Logo

Affy Partners with Imperial College London, MRC to Genotype Heart Disease, Diabetes, and Cancer

Dec 14, 2005

NEW YORK, Dec. 14 (GenomeWeb News) - Affymetrix said today that researchers at Imperial College London and the UK's Medical Research Council will use the company's GeneChip technology to study the genetic variations associated with cancer, cardiovascular disease, and diabetes.

 

The researchers will use Affy arrays to perform genotyping and gene-expression experiments. Affymetrix did not disclose which of its GeneChips the UK researchers will use.

 

Affymetrix said that the collaboration is part of its translational medicine program, an initiative designed to "accelerate clinical research and improve patient care by helping to bring more effective personalized tests and therapies to market faster."

 

Financial terms of the agreement were not provided.

Breaking News
The Scan

Y Chromosome Study Reveals Details on Timing of Human Settlement in Americas

A Y chromosome-based analysis suggests South America may have first been settled more than 18,000 years ago, according to a new PLOS One study.

New Insights Into TP53-Driven Cancer

Researchers examine in Nature how TP53 mutations arise and spark tumor development.

Mapping Single-Cell Genomic, Transcriptomic Landscapes of Colorectal Cancer

In Genome Medicine, researchers present a map of single-cell genomic and transcriptomic landscapes of primary and metastatic colorectal cancer.

Expanded Genetic Testing Uncovers Hereditary Cancer Risk in Significant Subset of Cancer Patients

In Genome Medicine, researchers found pathogenic or likely pathogenic hereditary cancer risk variants in close to 17 percent of the 17,523 patients profiled with expanded germline genetic testing.